0.000USD0.000åå ŽååŒÂ 07/24, 09:30 (ET)
228.91MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
Nautilus Biotechnology Inc
äž»èŠããŒã¿
1.700å§å€
1.786é«å€
1.00åºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.00%売買å転ç
1.770忥çµå€
1.700å®å€
2.00売買代é
æå€±é¡æ ªäŸ¡åçç
1.46PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-28.16%ç·è³ç£å©çç
4.31052é±é«å€
-0.00åºæ¥é«æ¯ç%
-70.78MçŽå©ç
126.47Mæ ªåŒæ°
-0.45171æ ªåœããå©çïŒEPSïŒ
0.82ããŒã¿å€
-33.69%èªå·±è³æ¬å©çç
0.62052é±å®å€
4.84%æ¯ãå¹
--ç²å©çç
228.91MæäŸ¡ç·é¡
-3.96ãªã¹ã¯ãªã¿ãŒã³
6.31%ãªã¹ã¯ç
Nautilus Biotechnology Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
çŸåšã®è©äŸ¡
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Nautilus Biotechnology Inc
NAUT
2
Ionis Pharmaceuticals Inc
IONS
26
ææšî
ææš
売ã(2)
äžç«(3)
è²·ã(1)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Nautilus Biotechnology Incã®äŒæ¥æ
å ±î
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Companyâs products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Companyâs Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
äŒæ¥ã³ãŒãNAUT
äŒæ¥åNautilus Biotechnology Inc
æé«çµå¶è²¬ä»»è
ãCEOãPatel (Sujal)
ãŠã§ããµã€ãhttps://www.nautilus.bio/
æ ªäž»çµ±èšî
ãããã質å
Nautilus Biotechnology IncïŒNAUTïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNautilus Biotechnology IncïŒNAUTïŒã®çŸåšã®æ ªäŸ¡ã¯1.76ã§ãã
Nautilus Biotechnology Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNautilus Biotechnology Incã®ãã£ãã«ãŒã·ã³ãã«ã¯NAUTã§ãã
Nautilus Biotechnology Incã®52é±é«å€ã¯ãããã§ããïŒ
îNautilus Biotechnology Incã®52é±é«å€ã¯4.31ã§ãã
Nautilus Biotechnology Incã®52é±å®å€ã¯ãããã§ããïŒ
îNautilus Biotechnology Incã®52é±å®å€ã¯0.62ã§ãã
Nautilus Biotechnology Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îNautilus Biotechnology Incã®æäŸ¡ç·é¡ã¯223.22Mã§ãã
Nautilus Biotechnology Inc (NAUT) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNautilus Biotechnology IncïŒNAUTïŒã®ç·åè©äŸ¡ã¯STRONG BUYã§ãç®æšæ ªäŸ¡ã¯4.00ã§ãã
Nautilus Biotechnology Inc (NAUT) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNautilus Biotechnology IncïŒNAUTïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.47ã§ãã